Market Overview

Osiris Therapeutics Reports Third Quarter 2012 Financial Results


Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the third quarter ended September 30, 2012.

Highlights and Recent Developments

  • Regained worldwide rights to Prochymal® and Chondrogen®
  • Reported $2.2 million of revenue from our Biosurgery products, Grafix and Ovation, during the third quarter – a 32% increase over the prior quarter and a greater than 6-fold increase over 3Q 2011.
  • Reported cash, receivables and short-term investments of $39.4 million as of September 30, 2012.
  • Promoted Lode Debrabandere, Ph.D. to the role of Chief Operating Officer.
  • Elected Hans Klingemann, M.D., Ph.D. to the position of Director to serve as a member of the company's Audit, Compensation and Nominating Committees.
  • Received notification from Swissmedic that Prochymal will be evaluated under its Rapid Authorization Procedures, a designation that cuts the evaluation period for promising new drugs in half.
  • Submitted a full proposal to the Biomedical Advanced Research and Development Authority (BARDA) after being selected for a Broad Agency Announcement (BAA) to fund advanced research and development of countermeasures, specifically for the use of Grafix in mass casualty thermal burn injuries.
  • Increased our U.S. intellectual property estate to 51 issued patents (154 worldwide). Recent additions cover the use of MSCs for graft-versus-host disease and inflammatory conditions, as well as methods of manufacturing and MSC quality.

“We are very pleased with how all aspects of our business performed this quarter,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics. “We have a very unique and exciting opportunity ahead of us. As we transition into a fully commercial entity, we will not relinquish the scientific leadership position we have created in cell therapy. Instead, we are leveraging our highly sophisticated understanding of this powerful technology to favorably differentiate our best-in-class products within the market place.”

Third Quarter Financial Results

Biosurgery product revenue rose 32% from the previous quarter to $2.2 million and over 6-fold from the third quarter of 2011. Gross profit from product sales rose to $1.4 million for the quarter or 66% of revenue. As of September 30, 2012, Osiris had $39.4 million of cash, receivables and short-term investments.

Research and development expenses for the third quarter of 2012 were $3.0 million, compared to $5.0 million incurred in the third quarter of 2011. General and administrative (G&A) expenses were $1.6 million for the third quarter of 2012 compared to $1.4 million for the same period of the prior year. Net cash used in operations for the three months ended September 30, 2012 was $1.6 million.

Webcast and Conference Call

A webcast and conference call to discuss the financial results is scheduled for today, November 5, 2012 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company's website at Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants).

An archive of the webcast will be available approximately two hours after the completion of the call through November 12, 2012. To access the archived webcast, visit the Investor Relations section of the company's website at

About Osiris Therapeutics

Osiris Therapeutics, Inc., having developed the world's first approved stem cell drug, Prochymal®, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 51 U.S. and 154 foreign patents.

Osiris, Prochymal, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for mesenchymal stem cells and biologic drug candidates and marketed Biosurgery products (including Prochymal®, Chondrogen®, Grafix® and Ovation®); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Condensed Balance Sheets
Amounts in thousands, except per share data
September 30, 2012 December 31, 2011
Current assets:
Cash $ 1,056 $ 1,661
Investments available for sale 36,159 45,604
Accounts receivable, net 2,231 728
Inventory 922 767
Deferred tax asset - 2,188
Prepaid expenses and other current assets   1,062     470  
Total current assets 41,430 51,418
Property and equipment, net 2,220 2,463
Restricted cash   318     392  
Total assets $ 43,968   $ 54,273  
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $ 5,002 $ 4,692
Capital lease obligations, current portion 44 -
Deferred revenue, current portion   -     3,333  
Total current liabilities 5,046 8,025
Long-term portion of capital lease obligations 173 -
Other long-term liabilities   387     430  
Total liabilities   5,606     8,455  
Stockholders' equity
Common stock, $.001 par value, 90,000 shares
authorized, 32,874 shares outstanding - 2012,
32,828 shares outstanding - 2011 33 33
Additional paid-in-capital 279,092 278,092
Accumulated other comprehensive income 15 20
Accumulated deficit   (240,778 )   (232,327 )
Total stockholders' equity   38,362     45,818  
Total liabilities and stockholders' equity $ 43,968   $ 54,273  
Condensed Statements of Operations
Amounts in thousands, except per share data
Three Months Ended Nine Months Ended
September 30, September 30,


2012   2011 2012   2011
Product revenues $ 2,151 $ 331 $ 4,914 $ 498
Cost of product revenues   732     139   1,671     209  
Gross profit   1,419     192   3,243     289  
Revenue from collaborative research agreements and royalties 232 10,242 3,776 30,861
Operating expenses:
Research and development 2,983 5,018 11,018 14,938
General and administrative   1,600     1,429   4,541     6,405  
  4,583     6,447   15,559     21,343  
(Loss) income from operations (2,932 ) 3,987 (8,540 ) 9,807
Other income, net   13     26   52     80  
(Loss) income before income taxes (2,919 ) 4,013 (8,488 ) 9,887
Income tax benefit (expense)   5     -   37     (43 )
Net (loss) income $ (2,914 ) $ 4,013 $ (8,451 ) $ 9,844  
Basic (loss) earnings per share $ (0.09 ) $ 0.12 $ (0.26 ) $ 0.30  
Diluted (loss) earnings per share $ (0.09 ) $ 0.12 $ (0.26 ) $ 0.30  
Weighted average common shares (basic)   32,871     32,826   32,854     32,818  
Weighted average common shares (diluted)   32,871     33,121   32,854     33,121  
Statements of Cash Flows
Amounts in thousands

Nine months ended,

Sept 30,
2012   2011
Cash flows from operating activities:
Net (loss) income $ (8,451 ) $ 9,844
Adjustments to reconcile net (loss) income
to net cash used in operating activities:
Depreciation and amortization 528 560
Non cash share-based payments 952 1,341
Provision for bad debts 11 -
Non cash expense- extension of expiration date of warrant to related party - 1,740
Changes in operating assets and liabilities:
Accounts receivable (1,514 ) 468
Inventory, prepaid expenses, and other current assets (747 ) 733
Deferred tax assets 2,188 -
Other assets - 165
Accounts payable and accrued expenses 267 21
Deferred revenue   (3,333 )   (30,720 )
Net cash used in operating activities   (10,099 )   (15,848 )
Cash flows from investing activities:
Purchases of property and equipment (57 ) (79 )
Proceeds from sale of investments available for sale 9,485 15,805
Purchases of investments available for sale   (45 )   (68 )
Net cash provided by investing activities   9,383     15,658  
Cash flows from financing activities:
Principal payments on capital lease obligations (11 ) -
Restricted cash 74 129
Proceeds from the issuance of common stock, net   48     22  
Net cash provided by financing activities   111     151  
Net decrease in cash (605 ) (39 )
Cash at beginning of period   1,661     1,442  
Cash at end of period $ 1,056   $ 1,403  

Osiris Therapeutics, Inc.
Erica Elchin, 443-545-1834

View Comments and Join the Discussion!